Breast Cancer Research Program anticipated funding opportunity for FY24

Armando Giuliano to receive the 2025 William L. McGuire Memorial Lecture Award

Armando E. Giuliano will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9-12 at the Henry B. Gonzalez Convention Center in San Antonio.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Tukysa improves HER2+ breast cancer, phase III trial shows

The phase III HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor Tukysa in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer has met its primary endpoint.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy

Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

Podcast The Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter and Paul Goldberg

Guest Editorial

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?

As every non-profit organization knows, it is our obligation to be purpose-driven. Most NPO founders and the people who work for them have been thrown into this space as a result of life experiences. It is our passion rather than a job to simply collect a paycheck.

October 10, 2025

Vol.51 No.37

By Erin Miller

Breast Cancer Research Program anticipated funding opportunity for FY24

YOU MAY BE INTERESTED IN

Armando Giuliano to receive the 2025 William L. McGuire Memorial Lecture Award

Tukysa improves HER2+ breast cancer, phase III trial shows

Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?

Renew today!

Subscriber content

Never miss an issue!

Login

Breast Cancer Research Program anticipated funding opportunity for FY24

YOU MAY BE INTERESTED IN

Armando Giuliano to receive the 2025 William L. McGuire Memorial Lecture Award

Tukysa improves HER2+ breast cancer, phase III trial shows

Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31Can health nonprofits survive in the current environment?

Never miss an issue!

Login

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?